Share on LinkedInShare on LinkedIn

ARTICLE · 16 NOVEMBER 2023

Making Waves – A Psychedelic Update

As discussed here and here, the psychedelic renaissance has spurred a renewed interest in the potential therapeutic benefits of substances such as psilocybin, LSD and tryptamines.

GlobalFood, Drugs, Healthcare, Life Sciences

As discussed here and here, the psychedelic renaissance has spurred a renewed interest in the potential therapeutic benefits of substances such as psilocybin, LSD and tryptamines. As the evidence of clinical efficacy builds, countries are now grappling with how to legalize the substances for medical treatment, yet still restrict illicit use of the drugs. In this article, we will summarize how Canada, the United States (US) and the European Union (EU) are regulating such drugs and are allowing them to be used in clinical trials. In addition, we will provide a brief overview of recent developments in Australia where medicines containing MDMA or psilocybin can be legally prescribed for limited purposes.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from